Diadexus, Inc. Stock

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

21-09-17	Diadexus, Inc. Went Out of Business	CI
18-06-08	Motion for Asset Sale Approved for Diadexus, Inc.	CI

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2K 42.49K 39.16K 36.65K 68.69K 4.68M 69.76K 462K 180K 2.28M 185K 181K 7.88M	P/E Ratio 2014	-3.26x	P/E Ratio 2015	-1.14x
Enterprise Value	5.29M 4.57M 4.21M 3.94M 7.39M 503M 7.5M 49.72M 19.38M 245M 19.85M 19.43M 847M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

21-09-17	Diadexus, Inc. Went Out of Business	CI
18-06-08	Motion for Asset Sale Approved for Diadexus, Inc.	CI
18-05-09	Motion for Asset Sale Filed by Diadexus, Inc.	CI
16-07-31	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
16-07-29	Motion for Asset Sale Approved for Diadexus, Inc.	CI
16-07-28	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
16-07-19	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
16-07-07	Motion for Asset Sale Filed by Diadexus, Inc.	CI
16-07-06	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
16-06-13	Diadexus, Inc. Filed for Bankruptcy	CI
16-06-10	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
16-05-23	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
16-04-29	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ULTRAGENYX PHARMACEUTICAL INC.	+1.54%	+11.14%	-35.05%	-53.20%	2.39B
SAREPTA THERAPEUTICS, INC.	+2.07%	-2.79%	-57.68%	-88.21%	1.62B
BIONOTE, INC.	+1.25%	+3.84%	-5.07%	-4.13%	325M
DK LIFE SCIENCE CO., LTD.	+2.65%	+3.39%	-35.41%	-	61.19M
Average	+1.50%	+4.94%	-33.30%	-48.51%	878.72M
Weighted average by Cap.	+1.73%	+5.73%	-41.16%	-62.58%

	2014	2015
Net sales	26.11M 22.55M 20.78M 19.45M 36.46M 2.48B 37.02M 245M 95.68M 1.21B 98M 95.91M 4.18B	17.88M 15.45M 14.23M 13.32M 24.97M 1.7B 25.36M 168M 65.53M 827M 67.12M 65.69M 2.86B
Net income	-8.47M -7.31M -6.74M -6.31M -11.82M -805M -12M -79.57M -31.02M -392M -31.78M -31.1M -1.36B	-7.17M -6.19M -5.7M -5.34M -10.01M -681M -10.16M -67.34M -26.26M -332M -26.89M -26.32M -1.15B
Net Debt	-198K -171K -158K -148K -276K -18.82M -281K -1.86M -725K -9.16M -743K -727K -31.72M	5.24M 4.53M 4.17M 3.9M 7.32M 498M 7.43M 49.25M 19.2M 242M 19.67M 19.25M 840M

Diadexus, Inc. Stock

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news : Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile